Prestigious magazine Forbes recently published the ‘50 most promising artificial intelligence (AI) companies in the US’.
The 2021 list features 31 companies appearing for the first time, while seven have qualified for three years in a row.
“Even as applications of machine learning and perception platforms become commonplace, a thick layer of hype and fuzzy jargon clings to AI-enabled software. That makes it tough to identify the most compelling companies in the space—especially those finding new ways to use AI that create value by making humans more efficient, not redundant,” says Forbes.
On this year’s list is Greek-owned startup ‘Intelligencia’, co-founded by Dimitris Skaltsas and Vangelis Vergetis.
Founded by a pair of longtime healthcare consultants, Intelligencia bucks the trend of pharmaceutical companies searching for drugs with their own AI.
Instead, it partners with existing pharmaceutical companies to provide software that’s meant to minimise the risk of failure in drug development and clinical trials.
The startup uses AI to predict the likelihood that a clinical trial will succeed and also provides input on how to improve the trial or what other areas of research to target.
“Our strong belief is that biotech needs to catch up to baseball and its own Moneyball moment is here,” says cofounder Vangelis Vergetis, referencing the 2011 film in which a small-budget baseball team used advanced analytics to outperform expectations.